Gynecologic Neoplasms Clinical Trial
Official title:
Pulse Pressure Variation With Augmented Ventilation to Predict Fluid Responsiveness in the Patients Undergoing Open Laparotomy Surgery
Verified date | March 2016 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Institutional Review Board |
Study type | Observational |
Pulse pressure variation (PPV) is a well-known and widely used dynamic preload indicator based on heart-lung interaction to predict fluid responsiveness. Generally, patients are considered to be fluid-responsive when the PPV value larger than 11-13%. However, several previous researches demonstrated that there is a zone of uncertainty (grey zone) in PPV. To predict fluid-responsiveness accurately in the patients with PPV within grey zone (9-13%), the investigators would evaluate the augmented PPV using augmented ventilation.
Status | Completed |
Enrollment | 38 |
Est. completion date | February 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Adult patients undergoing elective open laparotomy surgery. Exclusion Criteria: - Irregular heart beats, - cardiac arrhythmia, - moderate or severe valvular heart disease, - preoperative left ventriular ejection fraction less than 40%, - moderate t severe obstructive pulmonary disease, - preoperative need of inotropics infusion, - preoperative serum Cr > 1.3ml/dl, - moderate to severe renal or liver disease, - acute lung injury or acute lung problem, - coexisting open chest condition, - severe bradycardia, - patients with spontaneous breathing |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Augmented PPV (Pulse Pressure Variation) to predict fluid responsiveness | Augmented ventilation (12ml/kg) will be performed when the participant's PPV is within grey zone (9-13%). PPV value will be collected automatically by Intelivue philips patient monitor. Percentage changes in stroke volume index by EV1000 according to fluid loading were used as principal indicators of fluid responsiveness. Patients were classified as responders or non-responders when increases in SVI were = 10% or <10% after volume loading (crystalloid iv 6ml/kg). To test the abilities of augmented PPV to predict fluid responsiveness, areas under the receiver operating characteristics (ROC) curves of the responders [area under the curve (AUC) = 0.5: no better than chance, no prediction possible; AUC = 1.0: best possible prediction] will be calculated. | within 2 min from augmented ventilation | No |
Secondary | Conventional baseline PPV to predict fluid responsiveness | PPV value will be collected automatically by Intelivue philips patient monitor. | when patients PPV in grey zone, before augmented ventilation | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05185947 -
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
|
Phase 2 | |
Completed |
NCT02309944 -
Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients
|
N/A | |
Withdrawn |
NCT00328757 -
Safety of Regular Diet as the First Meal in Patients Who Underwent Surgical Treatment for Gynecologic Cancer
|
Phase 3 | |
Completed |
NCT02728830 -
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
|
Early Phase 1 | |
Completed |
NCT02935530 -
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
|
Phase 3 | |
Completed |
NCT02918461 -
Emerging From the Haze for Gynecologic Cancer Survivors
|
N/A | |
Completed |
NCT02786524 -
Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy
|
N/A | |
Terminated |
NCT04493619 -
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03101280 -
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
|
Phase 1 |